Caris Studies Optimal Sequencing in Informing Therapy Choices for Breast Cancer

  Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients.

The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking SG, across all HER2-negative groups. However, for patients with HR-negative and HER2-null tumors, SG showed better results when used as the first treatment. For other patient groups, there was no clear advantage to starting with one drug over the other.

"With the industry absence of head-to-head trials between the two most commonly used ADCs in breast cancer, real-world evidence remains our best tool to explore key questions around treatment scheduling and comparative effectiveness in similar patient populations," said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer.

Caris' real-world database drew from over 4,000 patients to uncover key differences that have the potential to assist clinicians in choosing treatment options to improve patient care. Additionally, results concluded that T-DXd and SG provided comparable benefits in patients with triple-negative breast cancer, highlighting the need for personalized treatment strategies based on tumor subtype.

"This study highlights the power of Caris to turn vast, real-world data into clinically actionable insights," said David Spetzler, MS, PhD, MBA, President of Caris. "Caris is leading the charge in precision medicine by combining advanced AI and vast real-world data to illuminate paths toward more personalized care. It's not just innovation; it's a reimagining of how science meets treatment."

The publication can be viewed in its entirety on the Caris Life Sciences website.

https://www.kxan.com/business/press-releases/cision/20250813DA50325/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-informing-therapy-choices-for-breast-cancer-subgroups/